Rubenstein, J L <br/><br/>
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.  [electronic resource] 

 -  Neoplasia (New York, N.Y.)   
 - 306-14 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1522-8002 
<br/><br/><label>Standard No.: </label>10.1038/sj.neo.7900102  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies--therapeutic use<br/>Brain Neoplasms--blood supply<br/>Endothelial Growth Factors--antagonists & inhibitors<br/>Female<br/>Glioblastoma--blood supply<br/>Humans<br/>In Situ Nick-End Labeling<br/>Lymphokines--antagonists & inhibitors<br/>Neovascularization, Pathologic--prevention & control<br/>Rats<br/>Rats, Nude<br/>Survival Rate<br/>Time Factors<br/>Transplantation, Heterologous<br/>Tumor Cells, Cultured<br/>Vascular Endothelial Growth Factor A<br/>Vascular Endothelial Growth Factors